Kyunghee Pharmaceutical

NBK Pharm Co., Ltd. (formerly known as Kyunghee Pharmaceutical Co., Ltd.) is a South Korean pharmaceutical company specializing in the development, manufacturing, and commercialization of generic drugs, high-content vitamins, and natural product-based therapeutics. Originally established in 2003 as Alpha M&M, the company underwent significant restructuring and was renamed to Kyunghee Pharmaceutical in 2012, before adopting its current name, NBK Pharm, in 2019. The company's commercial portfolio includes specialized prescription medications, over-the-counter products, and health supplements, notably its proprietary high-dose vitamin B formulation, Ventive Tab. NBK Pharm's research and development pipeline focuses on natural drug candidates, including NBK01 for rheumatoid arthritis, NBK02 for respiratory diseases, and NBK03, an oat-extract-based treatment for hearing loss licensed from Chonnam National University Hospital. Operating a GMP-certified manufacturing facility in Cheonan, South Korea, the company collaborates with major domestic pharmaceutical firms and contract sales organizations to expand its market presence.